Roy F. Chemaly
Advanced in Respiratory Syncytial Virus (RSV) Infection

Dr. Roy F. Chemaly

Infectious Disease
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
28 Years of Experience
Advanced in Respiratory Syncytial Virus (RSV) Infection
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roy Chemaly is an Infectious Disease provider in Houston, Texas. Dr. Chemaly has been practicing medicine for over 28 years and is rated as an Advanced provider by MediFind in the treatment of Respiratory Syncytial Virus (RSV) Infection. His top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Parainfluenza, and Febrile Neutropenia.

His clinical research consists of co-authoring 234 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Respiratory Syncytial Virus (RSV) Infection.

Specialties
Infectious Disease
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Efficacy of Combination Baloxovir and Oseltamivir Therapy in Influenza Infected Immunocompromised Hosts
Efficacy of Combination Baloxovir and Oseltamivir Therapy in Influenza Infected Immunocompromised Hosts
Enrollment Status: Recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Baloxavir Marboxil, Oseltamivir
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Enrollment Status: Terminated
Publish Date: July 24, 2023
Intervention Type: Drug
Study Drug: Casirivimab+Imdevimab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
Enrollment Status: Completed
Publish Date: February 09, 2023
Intervention Type: Diagnostic test
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients With Adenovirus Viremia
A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients With Adenovirus Viremia
Enrollment Status: Withdrawn
Publish Date: July 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 7 Less Clinical Trials

234 Total Publications

Corrigendum to 'American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients' [Transplantation and Cellular Therapy 31 (2025) 624-638/ https://doi.org/10.1016/j.jtct.2025.06.016].
Corrigendum to 'American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients' [Transplantation and Cellular Therapy 31 (2025) 624-638/ https://doi.org/10.1016/j.jtct.2025.06.016].
Journal: Transplantation and cellular therapy
Published: October 18, 2025
Similar Doctors
Distinguished in Respiratory Syncytial Virus (RSV) Infection
Dr. Antonella Casola
Pediatric Infectious Disease | Infectious Disease | Pediatrics
Distinguished in Respiratory Syncytial Virus (RSV) Infection
Dr. Antonella Casola
Pediatric Infectious Disease | Infectious Disease | Pediatrics

Utmb Faculty Group Practice

301 University Blvd, 
Galveston, TX 
 (46.8 miles away)
409-772-2222
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Antonella Casola is a Pediatric Infectious Disease specialist and an Infectious Disease provider in Galveston, Texas. Dr. Casola is rated as a Distinguished provider by MediFind in the treatment of Respiratory Syncytial Virus (RSV) Infection. Her top areas of expertise are Respiratory Syncytial Virus (RSV) Infection, Parainfluenza, Relapsing Fever, and Typhus. Dr. Casola is currently accepting new patients.

Ella J. Ariza-Heredia
Advanced in Respiratory Syncytial Virus (RSV) Infection
Dr. Ella J. Ariza-Heredia
Infectious Disease
Advanced in Respiratory Syncytial Virus (RSV) Infection
Dr. Ella J. Ariza-Heredia
Infectious Disease

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ella Ariza-Heredia is an Infectious Disease provider in Houston, Texas. Dr. Ariza-Heredia is rated as a Distinguished provider by MediFind in the treatment of Respiratory Syncytial Virus (RSV) Infection. Her top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Respiratory Syncytial Virus (RSV) Infection, and Whipple Disease.

Experienced in Respiratory Syncytial Virus (RSV) Infection
Dr. Marcia A. Kielhofner
Infectious Disease
Experienced in Respiratory Syncytial Virus (RSV) Infection
Dr. Marcia A. Kielhofner
Infectious Disease

Inpatient Infectious Disease Consultants

2201 W Holcombe Blvd, Suite 305, 
Houston, TX 
 (0.1 miles away)
713-791-1020
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Marcia Kielhofner is an Infectious Disease provider in Houston, Texas. Dr. Kielhofner is rated as an Advanced provider by MediFind in the treatment of Respiratory Syncytial Virus (RSV) Infection. Her top areas of expertise are Nocardiosis, Hospital-Acquired Pneumonia, Pneumonia, and Endocarditis. Dr. Kielhofner is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chemaly's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile